Title: Preimplantation Genetic Testing & Ethics

Abstract:

Preimplantation Genetic Testing (PGT) has transformed reproductive medicine by enabling the identification of chromosomal abnormalities and monogenic disorders prior to embryo transfer. As its clinical applications expand—from improving IVF success rates to preventing heritable diseases—PGT also raises profound ethical considerations. This presentation explores the current scientific capabilities of PGT, including PGT-A, PGT-M, and PGT-SR, and examines the implications of emerging technologies such as polygenic risk scoring and non-invasive embryo assessment. Ethical themes such as informed consent, embryo selection, equitable access, potential misuse for non-medical traits, and the societal impact of genetic selection will be critically analyzed. Through a balanced discussion integrating clinical evidence, patient-centered considerations, and bioethical frameworks, this session aims to guide practitioners toward responsible and ethically grounded use of PGT in reproductive care.

Biography:

Dr. Zev Rosenwaks is a globally recognized leader in reproductive endocrinology and infertility, renowned for pioneering advancements in in vitro fertilization and preimplantation genetic testing. He currently serves as the Director of the Center for Reproductive Medicine in the United States, where he leads one of the world’s most distinguished programs in assisted reproductive technologies. A board-certified reproductive endocrinologist, Dr. Rosenwaks has decades of clinical, academic, and research experience, with a career dedicated to improving fertility outcomes and expanding the boundaries of reproductive genetics. His work has contributed significantly to the development of PGT techniques, optimization of IVF success rates, and ethical integration of genetics into clinical practice.